A proband with chylomicronemia, pancreatitis, and non-insulin-dependent diabetes (NIDDM) bears two different mutations in exon 3 of the lipoprotein lipase (LPL) gene: a missense mutation, 7sArg -> Ser, inherited through the paternal line and a truncation, "Tyr --Ter, through the maternal line. NIDDM appeared to be independently segregating. The R75S mutant was studied in extracts and media from transfected COS-1 cells. Detectable amounts of catalytically competent R75S LPL suggested destabilization of the active homodimer as with exon 5 mutants (Hata et al. 1992. J. Biol. Chem. 267: 20132-20139 
and how genetic variation affects phenotype. Roughly two dozen mutations have now been identified in propositi with LPL deficiency (5) . Rearrangements (6, 7) , splice site (8, 9) , and nonsense ( 10-13 ) mutations (stop codons or frameshifts in exons 3, 5, or 6) result in enzyme deficiency through mRNA instability or the synthesis of truncated, catalytically inactive proteins.
Most reported index cases, however, have been homozygotes or compound heterozygotes for missense mutations that cluster in exons 4-6 and encode residues in the NH2-terminal folding domain responsible for catalysis (5, 14) . Most of these mutations fail to involve residues participating directly in catalysis. Only two (D1 56N and D1 56G [ 15, 16 ] )2 involve the catalytic triad (132Ser, '56Asp, 241His) itself. The majority of missense mutations must therefore affect enzyme function by indirect mechanisms (5, 17, 18) . Type I hyperlipoproteinemia (familial hyperchylomicronemia) results either from LPL deficiency or from the absence of LPL cofactor, apolipoprotein C-II (apoC-II) ( 19) . Index cases typically present in infancy with intolerance to dietary fat, abdominal pain with or without pancreatitis, eruptive xanthomas, and severe hypertriglyceridemia with fasting chylomicronemia. Heterozygous carriers manifest age-dependent familial hypertriglyceridemia typically with reduced LDL and HDL cholesterol concentrations (type IV hyperlipoproteinemia) (5, 20) . However, increased LDL cholesterol has also been reported in obligate heterozygotes, consistent with familial combined hyperlipidemia (FCH). It was therefore suggested that LPL deficiency is involved in the pathogenesis of FCH (21 ) .
We recently described in vitro studies of exon 5 mutants known to result in clinical LPL deficiency (A176T, G188E, G195E, and S244T) (18) . Wild-type and mutant sequences were expressed in vitro in COS-l cells and heparin binding was assessed by high-resolution affinity chromatography. For all of these mutants a catalytically inactive protein with reduced affinity for heparin was detected in the culture media by a specific ELISA. Small amounts of enzymatically active LPL with an affinity for heparin identical to that of wild-type enzyme were recovered from cell lysates from one mutant, G 1 88E ( 18, 22) . Other evidence indicates that these mutations encode a potentially active but intrinsically unstable LPL homodimer, thus leading to LPL deficiency ( 18) .
A subset ofsusceptible patients develops severe hypertriglyceridemia in the context of poorly controlled NIDDM. Such individuals are believed to possess an independently inherited disorder of lipid metabolism (23) . On the assumption of Hardy-Weinberg equilibrium and a rough estimate ofthe prev-alence ofhomozygous LPL deficiency, we proposed that heterozygous LPL deficiency in combination with abnormalities in lipoprotein metabolism resulting from diabetes accounts for instances of diabetic lipemia (24) . Heretofore there has been no direct support for this hypothesis.
We now describe two previously unreported mutations in the LPL gene in siblings with type I hyperlipoproteinemia. One has overt non-insulin-dependent diabetes (NIDDM) and the other has mild diabetes of recent onset. These brothers proved to be compound heterozygotes for a nonsense (Y73Ter) and a missense (R75S) mutation, both in exon 3. The R75S mutant enzyme was transiently expressed in COS-1 cells and several of its biochemical properties were investigated. Lipoprotein phenotypes were examined in the extended pedigree in subjects with NIDDM homozygous for wild-type LPL, in carriers ofthe LPL mutations without NIDDM, and in a subject with NIDDM who carried the Y73Ter mutation.
Methods
Subjects. The proband in kindred 2062, a 43-yr-old male of German and English-Irish ancestry, was the offspring of a nonconsanguineous union (Fig. 1) . Lipemia was noted during infancy, and the subject recalled recurrent episodes of abdominal pain precipitated by dietary fat throughout childhood. As an adult, overt pancreatitis was documented on at least one occasion. Although the proband had never had xanthomas, he had been told that his spleen and possibly his liver were enlarged. During periods ofunrestricted fat intake plasma triglycerides were as high as 10,000 mg/dl (113 mM). His plasma, after standing overnight at refrigerator temperature, was described: "the upper 80% looked like whole milk, and the bottom was hazy yellow." With dietary fat restriction plasma triglycerides fell to -1,500 mg/dl (17 mM).
Although he was lean (178 cm tall; 74 kg; body mass index 23.4 kg/im2) the proband developed NIDDM at age 42 and was begun on oral sulfonylurea treatment with a subsequent glycated hemoglobin concentration of 5 .1% (normal range 5.3-8.3%). Three offspring, two sons and a daughter, were ostensibly healthy. The proband had divorced and remarried and blood from the children's biological mother was obtained by mail. Plasma lipoprotein analyses were performed according to Lipid Research Clinics guidelines on venous blood samples collected after subjects had fasted 12-15 h. The 11-yr-old daughter's lipids were resampled after abnormalities were found initially; no changes in dietary habits were made in the interim. These studies were conducted with informed consent under protocols approved by the Institutional Review Board at the University of Utah.
Lipase activity in postheparin plasma, culture media, and fast protein liquid chromatography column fractions was measured as described in detail elsewhere (10, 25) . For plasma samples, LPL and hepatic lipase activities were calculated as the fractions oftotal lipolytic activity that were and were not inhibited, respectively, by a polyclonal antibody to LPL. Lipoprotein lipase masswasdeterminedbyacompetitive enzyme-linked immunosorbent assay using a monoclonal antibody to bovine LPL (5D2) against standards of purified bovine LPL (10) . Results ofpre-and postheparin mass and activity were compared to previously published values given for normal individuals (21, 26) . Analytical heparin-Superose chromatography was also performed as described previously (10) .
Hydrolysis of the short-chain fatty acid ester (p-nitrophenyl butyrate, PNPB) was assayed with minor modifications ofpublished methods (27) (28) (29) . Working PNPB substrate (Sigma Chemical Co., St. Louis, MO) (1.0 mM) was prepared by the addition of Triton X-100 (150 mM) to the desired amount of PNPB (50 mM) in acetonitrile (Mallinckrodt Special Chemicals Co., Paris, KY) and assay buffer was added dropwise with stirring (27) . The final Triton concentration, 0.25 mM, was taken from a published estimate of the critical micellar concentration, 0.20±0.05 mM (29) . Final concentrations in the assay were as follows: sodium phosphate 0.05 M, NaCl 0.1 M, glycerol 10.0% (wt/vol); heparin 10.0 ,g/ml, Triton X-100 0. 25 Aliquots (15 Ml) of genomic DNA were enzymatically amplified using exon 3 forward and reverse flanking primers. The product was denatured in 200 Ml of0.4 M NaOH/25 mM EDTA and 90 Ml ofthe mixture were spotted in duplicate onto a nylon membrane (BioTrace RP, Gelman Sciences, Inc., Ann Arbor, MI) using a Bio-Dot SF apparatus (Bio-Rad Laboratories, Richmond, CA). After neutralization with 90 Ml of 3 M Na-acetate buffer (pH 5.4), DNA was cross-linked to the membrane in a Stratalinker 1800 (Stratagene, Inc., La Jolla, CA). The labeled probes were hybridized to the membrane in the presence of 0.5% SDS/0.9 M NaCl/ 1 mM EDTA/50 mM Na-phosphate buffer (pH 7.2) at 37°C for 3 h. After hybridization, the membranes were washed two times in 0.15 M NaCl/ 15 mM Na-citrate buffer (pH 7.0) at room temperature, and then washed at 1 to 2°C below the calculated melting temperatures for the mutant and normal alleles, respectively, and submitted to autoradiography.
Expression in COS-J cells. The missense allele was expressed in cultured COS-1 cells (ATCC Catalogue No. CRL1650) plated at an initial density of 1 X 106 per 10-cm dish and maintained in 5 ml of Dulbecco's modified Eagle's medium (DME, Gibco, Grand Island, NY) with 10% FCS for 48 h. They were transfected with plasmid DNA (6 Mg/dish) following the DEAE-dextran protocol of Selden et al. (32) with modification. I h after DNA addition, chloroquine was added to the medium at a final concentration of 80 MM. After 4 h of incubation at 37°C, 5 ml of 10% DMSO/ PBS was added to each plate for 2 min at room temperature. After aspiration of this solution, each plate was washed with 5 ml of lx PBS. This solution was replaced with 5 ml of complete medium and the culture was incubated at 37°C. 30 h after transfection, 5 ml of serum-free DME medium with heparin at a final concentration of5 U/ml, was substituted and the culture incubated for another 8 h before medium and cells were harvested. Cell extracts were prepared by washing the cells twice with l x PBS, adding 1 ml of cell lysis buffer [2 mg/ml deoxycholic acid, 0.08 mg/ml Nonidet P-40, 0.05 mg/ml heparin, 0.1 M Hepes buffer (pH 7.5)] per plate, and detaching cells with a cell scraper. The cell extracts were homogenized in a Dounce tissue grinder, centrifuged at -15,000 g for 10 min at 4VC, and the supernatants were collected. The media and cell extracts were flash-frozen and stored at -70'C until analyzed.
Results
Plasma lipids and lipoproteins from the nuclear family are shown in Table I . The proband's (subject no. 3001) values were typical for type I hyperlipoproteinemia. His two sons (4103 and 4104) were normolipidemic, consistent with observations in young carriers of the G188E mutation previously reported (20, 22) . On the first sampling the 11-yr-old daughter (4105) had increased age-and gender-specific total and LDL cholesterol concentrations (=95th percentile and > 95th percentile, respectively). This pattern, with hypertriglyceridemia in some family members and hypercholesterolemia others, could be consistent with FCH (33) . However, when the daughter was retested 1 yr later without any interim dietary changes, her values were entirely normal (second values in Table I ).
Preheparin plasma LPL mass in the proband, determined by competitive ELISA and normalized to a bovine LPL standard, was 19 ng/ ml rising after heparin administration to 51 ng/ml, a value lower than previously reported for normal subjects (21) , and similar to mean values reported for LPL-deficient subjects inferred to have catalytically defective enzyme protein (26) . Postheparin plasma LPL activity in the proband was severely reduced (13 nmol/ ml per min, -6% of the reported normal mean) whereas hepatic triglyceride lipase activity was 370 nmol/ml per min, within the range of normal subjects in this laboratory.
No mutations were revealed in exons 4, 5, or 6 (data not shown) by chromatographic analysis of enzymatically amplified genomic DNA from the proband (3001), his offspring (4103, 4104, 4105), or their mother (3101). On analysis of exon 3 (Fig. 2) the mother, 3101, exhibited two major bands identical with those in normolipidemic controls, whereas the proband had four bands, two of which were clearly different from hers. The two sons possessed one of the anomalous paternal bands, and their daughter the other. This suggested that the proband was a compound heterozygote for two different mutant alleles, and that his offspring were obligate heterozygotes for one or the other of them.
The proband's two abnormal bands were eluted from polyacrylamide gel and used as templates for thermocycling reactions with primers flanking exon 3, lengthened with the universal M 13 priming sequence (5 '-TGTAAAACGACGGCCAGT-3'). Automated dideoxy sequencing showed that the proband bore two mutant alleles, one at nt 480 (A --C) coding for a "Arg --Ser substitution, and the other at nt 474 (C --A)
changing "Tyr to a stop codon. These conclusions were confirmed by hybridization with allele-specific oligonucleotide probes complementary to the mutant alleles (Fig. 2) .
The functional significance of the R75S mutation was investigated through transient expression of wild-type (arginine75) and mutant (serine75) LPL (Fig. 3) . The second, higher-affinity peak catalyzed the hydrolysis of both triolein in the presence of serum activator, and micellar PNPB in the absence of added serum. The first peak had no detectable enzymatic activity against either substrate. In contrast to media from wildtype-transfected COS-1 cells, medium from those transfected with R75S mutant LPL exhibited a large, low-affinity mass peak and markedly reduced but detectable immunoreactive LPL in the second, higher-affinity peak. As with wild-type LPL, fractions in peak I were catalytically inactive. Peak II fractions from media ofR75S transfectants exhibited low activity against triolein which was nevertheless significantly above background for the assay.
Cell lysates and media from wild-type-transfected COS-1 cells showed esterase activity against PNPB in the early fractions ( 1-20) of the heparin-Superose chromatogram (Fig. 4) . 206 Wilson et al. This activity was not inhibited by the addition of anti-bovine LPL antibody (7640A) under conditions that inhibited bovine LPL by 87% (data not shown) and thus, appeared to be nonspecific. Since the majority of the nonspecific esterase activity eluted from the column in the first 20 ml, LPL-catalyzed PNPB hydrolysis could be identified as a distinct peak ofactivity eluting at the same molarity as LPL activity and mass (peak II) in the standard assay (Fig. 4) . No peak of PNPB hydrolysis was observed to coincide with peak I. The rate of hydrolysis of PNPB relative to triolein by peak II fractions from R75S-transfected cell medium was similar to that observed for wild-type transfection (4.8 vs. 3.3 pmol/min per ng LPL protein, respectively; Figs. 3 and 4) . When serum activator was omitted, the hydrolysis of triolein by peak II fractions from R75S-transfected media was reduced 83% by peak-area comparison (fractions eluting between 30 and 32 ml; 8.83 nmol/min per ml vs. 1.74 for assays with and without serum, respectively) consistent with apoC-II dependence, and implying that apoC-II was binding to the mutant enzyme. Although these results with R75S may not be quantitatively precise, having been performed at the limit of assay sensitivity, the two experiments nevertheless led to the same conclusion.
Thus, as with previously reported missense mutations from our own and other laboratories ( 18, 22, 34) , R75S resulted in the production of a catalytically inactive protein having reduced affinity for heparin (Fig. 3 B) . There was, however, a second, higher-affinity species secreted into the culture medium and representing a small fraction of the total mass, that was shown to be catalytically active (eluting at -31-32 ml,
Figs. 3 B and 4 B).
Screening of the extended pedigree (Table I and Fig. 1 Diabetes and hyperlipidemia appeared to segregate independently in the maternal lineage; two living individuals were veri-A previously unreported patient with type I hyperlipoproteinemia presented as an adult with a history of hypertriglyceridemia and abdominal pain beginning in childhood, and episodes ofdocumented pancreatitis and NIDDM (type II diabetes mellitus) of adult onset. It is possible that type I hyperlipoproteinemia, through repeated bouts of pancreatitis, might lead to pancreatogenous diabetes. However, a family history of NIDDM in nonhypertriglyceridemic members and lack ofevidence for pancreatic calcification or exocrine deficiency in the propositus make this interpretation an unlikely sole explanation for the occurrence of diabetes (35) . This same argument can be applied to other hypertriglyceridemic diabetic pedigree members. Conversely, independently inherited NIDDM, leading to increased production of triglyceride-rich lipoproteins (36) , could be expected to exacerbate hypertriglyceridemia in the presence of defective LPL alleles (23, 24, 37) .
The proband and a younger brother were discovered to be compound heterozygotes for two previously undescribed mutations in the LPL gene. Both were in exon 3: one was missense (R75S) whereas the other (Y73Ter) resulted in a premature stop codon. On the basis of these and other recently reported mutations (38) (39) (40) , exon 3 must be included with exons 4-6 in the highly conserved region coding for residues in the first folding domain, a region whose integrity is evidently critical to the function of the mature enzyme. Missense mutations that directly involve residues participating in catalysis are the exception: Asp'56(D156N [15] and D156G [15, 16] ) situated in the catalytic triad-homologue ofpancreatic lipase (41) are the only known examples. Thus other mechanisms must be invoked to explain enzyme deficiency caused by the majority ofthese substitutions. In principle, such mutations could involve any of several discrete functional domains: those binding the LPL cofactor, apoC-II, heparin, or lipid substrates (1) . The missense R75S sequence was therefore transfected into COS-1 cells so that properties of the mutant LPL recovered from media and cell extracts could be studied.
Since wild-type LPL requires apoC-II for full activity, the existence of an apoC-II binding site on LPL has been postulated. The site has recently been localized to the NH2-terminal, first folding-domain by analysis of chimeric enzymes (14) . 208 Wilson et al. Candidate regions include the NH2-terminal 50 residues and sequences with high positive charge (R or K) including consensus heparin-binding sites (42 (Fig. 3 A) , the inactive, low-affinity peak accounted for the great majority of total immunoreactive mass in media from R75S transfectants (Fig. 3 B) . Nevertheless, the specific activity of the R75S mutant against triolein, calculated for the higher-affinity peak, was of the same order as wild-type enzyme (0.40 vs. 0.77 nmol/ min per ng LPL mass). Thus, a small amount of catalytically competent R75S enzyme was secreted.
What are the molecular species in the two peaks eluted from heparin-Superose, one active and the other not? A great deal of evidence (43) (44) (45) (46) (47) (48) (49) , summarized by Hata et al. ( 18) , supports the conclusion that active LPL consists oftwo monomeric subunits combined as a homodimer at physiological pH and ionic strength (45, 48) , possibly oriented in a head-to-tail configuration (50) . Other evidence indicates that enzymatically active LPL has a higher affinity for heparin than does inactive LPL (51 ). Thus we concluded that the higher affinity, enzymatically active peak eluting from heparin-Sepharose may be present as a homodimer under conditions ofthe assay ( 18). However LPL is likely to dissociate into its subunits at NaCl concentrations of0.8 M or more (52) (53) (54) . Therefore LPL may emerge from the column as a stable, dissociated monomer when it is eluted with -1.0 M NaCl, and then reassociate into the active dimer when it is diluted in the activity-assay buffer. The lower-affinity peak ofwild-type LPL, which never exhibits activity, may therefore be irreversibly denatured.
Insight into the mechanism by which missense mutations result in the loss of LPL activity has been provided by pulsechase experiments with four naturally occurring mutations in exon 5 (A176T, G188E, G195E, and S244T) expressed in COS-1 cells (18) . With one exception, G188E, the mutant products consisted solely of the low heparin-affinity species. The four LPL mutations previously reported, along with R75S, thus appear to represent a class of inherently unstable enzyme molecules, exhibiting a continuum of functional impairment. The most severe of these was S244T from which no activity whatsoever could be recovered, and in comparison to wild type, reduced amounts of the inactive species were secreted. R75S appears to be at the other end of this continuum, yielding substantial amounts of immunodetectable LPL protein in medium from COS-1 cells, small amounts of which retained catalytic activity.
The profound destabilizing effect ofwidely separated mutations in the first folding domain of LPL is consistent with the recognized importance of three-dimensional topology in the function of the lipases whose structure has been determined crystallographically, i.e., pancreatic lipase and fungal lipases. Despite undetectable sequence homology, human pancreatic and Geotrichum candidum lipases closely resemble each other in the conformation of their central ,3-sheet and in the location of two of the three residues (Ser, His) making up the catalytic triad (55); thus in these diverse representatives of the lipase superfamily (55, 56) , overall topology is conserved even though their primary sequences diverge (55) . The existence of stringent conformational requirements appears to explain how naturally occurring missense mutations, dispersed in the NH2-terminal folding domain of LPL and affecting residues unlikely to participate directly in catalytic or binding reactions, lead to lipoprotein lipase deficiency.
The phenotypes expressed in the extended pedigree were of interest. Two of the proband's offspring and a niece, heterozygous for the missense R75S allele, had entirely normal plasma lipid and lipoprotein concentrations. Of the seven carriers 40 yr of age and older who were phenotyped, hypertriglyceridemia and/or reduced HDL cholesterol was detected in five, consistent with variable, age-dependent expression of familial hypertriglyceridemia in heterozygous carriers previously observed among G188E carriers (20, 57 ).
The proband's daughter (4105) who carried the null allele, had mildly increased total-and LDL cholesterol on one occasion, but not on repeat measurement. Even though this could be consistent with the phenotype, FCH (33) , it could just as well be coincidental given the variability ofplasma LDL during puberty and adolescence (58) ; it could also have been the result oflaboratory error. Alternatively, different LPL mutations may eventually prove to have different associated phenotypes, a possibility that could account for the presence of increased LDL cholesterol in some pedigrees (21, 57) but not others (20) . Nevertheless, lipid and lipoprotein analyses of genotypically proven heterozygotes have with rare exceptions (57) either been normal or have had hypertriglyceridemia, increased VLDL cholesterol, and reduced HDL cholesterol (type IV hyperlipoproteinemia) (5) . Although final resolution ofthis issue will require study ofa larger number ofpedigrees with informative mutant alleles, evidence now available indicates that carriers of LPL mutations rarely if ever manifest FCH.
Since an allele for an unstable mutant protein segregates in one branch of the pedigree while a null allele segregates in the other, one can also ask whether the secretion of low levels of catalytically competent enzyme such as demonstrated in vitro for the R75S mutation might delay or ameliorate the expression of hypertriglyceridemia. The clinical disorder observed in the proband's brother, also shown to be a compound heterozyote, is arguably milder than that described for classical LPL deficiency ( 19) . Nevertheless, observations of other individuals affected by similar mutations would be necessary to establish that this is other than expected variation in the classical phenotype.
Finally, the data obtained in this pedigree bear on the hypothesis, introduced a number of years ago by Brunzell and others, that individuals with NIDDM manifesting severe lipemia have another independently inherited defect in lipoprotein metabolism (23, 24, 37) . Subject 2107 with severe hypertriglyceridemia, xanthomatosis, pancreatitis, and NIDDM appears to be the first documented example ofthe predicted result ofsegregating hyperlipidemia genes in diabetic individuals (23, 24) . Her sibship fortuitously contained diabetic individuals without LPL mutant alleles, and nondiabetic carriers of LPL mutations. In neither of the latter instances did more than mild-tomoderate hypertriglyceridemia result. Thus, the role of independently segregating hyperlipidemia genes in the pathogenesis of severe diabetic hypertriglyceridemia can now be supported by direct evidence. It does not seem farfetched to anticipate that additional subjects with severe diabetic lipemia will be found to carry mutations in other genes affecting lipoprotein synthesis or removal, as well as additional dysfunctional LPL alleles.
